Cellyan Biotechnology Co. Ltd
HKPD evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for HKPD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · HKPD
Cellyan Biotechnology Co. Ltd is a Hong Kong-based holding company that provides supply chain services for over-the-counter (OTC) pharmaceutical products, primarily in Mainland China, and is currently operating with minimal cash and a net loss.
Key risk: Intense industry competition
Market Cap
$16.8M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Sep 30, 2025.
Cellyan Biotechnology Co. Ltd is a Hong Kong-based holding company that provides supply chain services for over-the-counter (OTC) pharmaceutical products, primarily in Mainland China, and is currently operating with minimal cash and a net loss.
- Cellyan provides supply chain services for OTC pharmaceutical products, focusing on the Mainland China market [sec · filed 2026-08-07].
- The company reported a net loss of $(27,056) for the year ended March 31, 2025, compared to a net profit of $1,329,717 in the prior year [sec · filed 2026-08-07].
- As of September 30, 2025, the company had cash and equivalents of $0.2M, shareholders' equity of $5.4M, and total debt of $1.5M [sec].
- The company believes its cash on hand, operating cash flows, and future financing will be sufficient for at least 12 months from the date of its August 2026 report, but may need additional cash for changed business conditions or opportunities [sec · filed 2026-08-07].
- The company faces intense competition in the supply chain services industry, particularly from large logistics providers that may bring OTC pharmaceutical services in-house [sec · filed 2026-08-07].
What works
- The company has a strategic focus on the OTC pharmaceutical supply chain, a specialized niche that may offer differentiation from general logistics providers [sec · filed 2026-08-07].
- Management plans to invest in technology, such as smart shipping equipment and a cross-border OTC service platform, to improve efficiency and customer acquisition [sec · filed 2026-08-07].
- Controlling shareholders have indicated readiness to provide financial support if the company faces cash shortages [sec · filed 2026-08-07].
What to weigh
- The company reported a net loss of $(27,056) for the year ended March 31, 2025, a significant decline from a net profit of $1,329,717 in the prior year [sec · filed 2026-08-07].
- Cash and equivalents were only $0.2M as of September 30, 2025, indicating a very tight liquidity position [sec].
- The company faces intense competition, especially from large logistics providers that may decide to offer OTC pharmaceutical supply chain services in-house [sec · filed 2026-08-07].
- The company may need additional cash resources if business conditions change or if it pursues investment or acquisition opportunities [sec · filed 2026-08-07].
From the filings
Quoted directly from source documents.
The company reported a net loss for the year ended March 31, 2025.
“Net (loss) profit for the years ended March 31, 2025 and 2024 was $(27,056) and $1,329,717, respectively, a decrease of $1,356,773, or 102%.”
SEC filings · August 7, 2026
The company faces intense competition in its industry.
“We face intense competition in the broader supply chain services industry, especially if large logistics service providers who hire our expertise decide to expand their offerings to include OTC pharmaceutical related supply chain services in-house, which could adversely affect our results of operations and market share.”
SEC filings · August 7, 2026
The company believes it has sufficient liquidity for at least 12 months.
“the Company believes that its cash on hand, operating cash flows and future financing cash inflow will be sufficient to fund its operations over at least the next 12 months from the date of this report.”
SEC filings · August 7, 2026
The company plans to invest in technology to improve its supply chain services.
“We plan to update our software system by developing a comprehensive cross-border OTC pharmaceutical service platform that addresses our current supply chain challenges such as fragmentation and improves customer acquisition.”
SEC filings · August 7, 2026
Risks & what to watch (4)›
Key risks
- Intense industry competition — Large logistics providers may bring OTC pharmaceutical supply chain services in-house, threatening market share [sec · filed 2026-08-07].
- Limited cash and net loss — Cash of $0.2M and a net loss of $(27,056) as of March 31, 2025, raise liquidity concerns [sec] [sec · filed 2026-08-07].
- Need for additional financing — The company may require extra cash for changed business conditions or growth opportunities [sec · filed 2026-08-07].
- Dependence on China market — Operations are concentrated in Mainland China, exposing the company to local regulatory and economic risks [sec · filed 2026-08-07].
What to watch
- Ability to return to profitability and generate positive operating cash flow [sec · filed 2026-08-07].
- Progress on technology investments, including the cross-border OTC service platform [sec · filed 2026-08-07].
- Any need for additional financing or shareholder support given low cash reserves [sec] [sec · filed 2026-08-07].
- Competitive dynamics, especially moves by large logistics providers into OTC pharmaceutical supply chain [sec · filed 2026-08-07].
Sources: SEC filings · Generated August 10, 2026 · How we verify sources →
Run Cellyan Biotechnology Co. Ltd through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Cellyan Biotechnology Co. Ltd facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2
Total value held
$29K
| Holder | Shares | Value |
|---|---|---|
| stonex group inc. | 39,395 | $22K |
| two sigma investments, lp | 10,832 | $6K |
Short Interest
as of Apr 21, 2026- % of float
- 0.0%
- Days to cover
- 0.0
- Shares short
- 380
- Daily short volume (Aug 28, 2026)
- 48.4%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
HKPD short interestFrequently asked questions
What is the AI investment thesis for Cellyan Biotechnology Co. Ltd?
Cellyan Biotechnology Co. Ltd is a Hong Kong-based holding company that provides supply chain services for over-the-counter (OTC) pharmaceutical products, primarily in Mainland China, and is currently operating with minimal cash and a net loss.
Who is the CEO of Cellyan Biotechnology Co. Ltd?
Mr. Chenyu Liang is the chief executive officer of Cellyan Biotechnology Co. Ltd (HKPD).
Where is Cellyan Biotechnology Co. Ltd headquartered?
Cellyan Biotechnology Co. Ltd (HKPD) is headquartered in Yau Tong, Hong Kong.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.